International Journal of Advance and Applied Research (IJAAR)
Peer Reviewed Bi-Monthly
ISSN – 2347-7075
Impact Factor – 5.136
Vol.5 No.1 Sept– Oct 2017

EXAMINING THE CREATION OF PREDNISOLONE NANOPARTICLE-CONTAINING ORAL DISPERSIBLE TABLETS FOR THE TREATMENT OF "PAEDIATRIC""ASTHMA"

Mrs. Savita
Principal, Department of Pharmacy,
J.R. Kissan College of Pharmacy and Health Science,
Rohtak, Haryana, India.

ABSTRACT:

The term "asthma" refers to a chronic inflammatory condition. The "Reserve airflow obstacles" are what define it. The term "bronchospasm" is useful for describing this condition. Dispersible pill use causes various sorts of "hypersensitivity reactions" in "paediatric" "asthma". Animatedly dissolving "inter-oral dose" forms that were used to replace "prednisolone" were described as "Orodispersible films" (ODF) in earlier research. The PDS is bought in nearby stores. The components of this research were obtained through cooperation with the "biotechnology" laboratory. Other ingredients include "lactose, microcrystalline cellulose, magnesium stearate". Nanoparticles that have been prepared are gathered and weighed. The yield of "nanoparticles" doesn't vary greatly. These are significant forms that "asthma" patients can make use of.

Keyword: *Reserve airflow obstructions, Bronchospasm, paediatric, Asthma, prednisolone nanoparticles*

INTRODUCTION:

"Asthma" is considered a chronic inflammatory disease. It is characterised by the "Reserve airflow obstructions". "Bronchospasm" is also helpful to characterise this disease. The use of dispersible tablets in "paediatric" "Asthma" has a "hypersensitivity reaction" in different types. The "atopic and nonatopic" types of "Asthma" are disclosed where "prednisolone nanoparticles" are utilised. It is considered a "synthetic glucocorticoid" (Tawfik *et al*. 2021).

The aim of this research is to develop "prednisolone nanoparticle-containing Oral disposable tablets" for the treatment of "paediatric""Asthma". The objectives of the research are also focused on "prednisolone nanoparticles"

and developing a suitable therapeutic system for patients with "paediatric""Asthma".

LITERATURE REVIEW:



Figure 1: Blank nanoparticles
(Source: Hanafy et al. 2019)

In the previous literature, "Orodispersible films" (ODF) were discussed as animatedly dissolving "inter-oral dosage" forms that were placed as a substitute for "prednisolone". Nowadays the engineering process has been developed for pharmaceutical applications. It is conducted in order to increase the dissolution rate of "low-soluble drugs". It leads to a "substantial increase in bioavailability" (Nieto González *et al*. 2021).



Figure 2: Blank nanoparticles
(Source: Hanafy et al. 2019)

"Nanoparticle engineering" has enabled poorly soluble drugs and formulate as a particle that is combined with "pharmaceutical excipients". The "optimisation of oral drug delivery systems" is a challenging task. Consequently, dispersible tablets have been invented, that contain "PDS nanoparticles". The orally disintegrating tablets are easy to administer and it is better for the patient's compilers (Nieto González *et al*. 2021). The loose drugs are incorporated into ODFs. It is confounded with the aid of MSNs.

METHODS:

The PDS is purchased from nearby shops. The laboratory of "biotechnology" also collaborated to get the components of this research. The "lactose, microcrystalline cellulose, magnesium stearate" and other components. "CS nanoparticles" are prepared primarily using the "ionotropic gelation method". The factorial design for the development of "ODT" is essential (Iftikhar *et al*. 2020).



Figure 3: Ingredients physical mixture
(Source: Hanafy et al. 2019)

The statistical analysis is conducted on "prednisolone nanoparticles". The "aerosol solvent extraction technology" was used to synthesise "prednisolone nanoparticles" under the "vicinity of a hydrophilic polymer" as well as a surfactant. The "ternary mixture" is used to prepare "prednisolone

nanoparticles". The use of "prednisolone, sodium dodecyl sulphate" and other components mixture is required (Cornilă*et al.* 2021). This mixture is dissolved in methanol. The reaction "vessel" is used to fill the supercritical carbon dioxide. The presentation of "CS-PDS nanoparticles" is displayed below

"Batch"	"Yield"	"EE"	"DL"	"PSD"	"Solubility"
F1	70.12	60.13	10.32	750	431
F2	84.15	75.15	13.46	468	465
F3	85.15	86.13	34.39	255	53
F4	90.26	61.23	23.34	310	489

This range is articulated with PDS formation through solubility and the "chitosan and encapsulation efficiency".

RESULTS AND FINDINGS:



Figure 4: Spectra of nanoparticles
(Source: Hanafy et al. 2019)

The prepared nanoparticles are Collected and weighed. There are no wide variations in the yield of "nanoparticles". Those are considerable formats that can be utilised for "Asthma" patients (Khater*et al*. 2022). After conducting the

research, it has been found that the minimum loss of “nanoparticles” is configured at a higher speed with a “maintained cooling temperature”. The temperature must be “-100 degree Celsius”. The “commercially variable doses” are formed for “paediatric” patients such as tablets, capsules and other medicines (Salunke*et al.* 2021). It has also been found that the patient is facing “compliance and inability” to swallow the dosage. “Prednisolone” is used as an “anti-inflammatory agent”. It indicates the condition of “corticosteroid therapy” for “Asthma” patients. It is likely to be beneficial because it includes the clearance of “allergic disorders”, “leukaemia”, “thrombocytopenic purpura” and other issues.

CONCLUSION:

It can be concluded that the utilisation of “PDS and ODT” is successfully prepared through the inclusion of the compression method. The aim of this research is considered successful as it provides advantages for the patients. The “ODT” is considered an advanced and “potential technology” for “paediatric” patients.

REFERENCES:

1. Cornilă, A., Iurian, S., Tomuţă, I., &Porfire, A. (2022). Orally Dispersible Dosage Forms for “paediatric” Use: Current Knowledge and Development of Nanostructure-Based Formulations. Pharmaceutics, 14(8), 1621. https://www.mdpi.com/1999-4923/14/8/1621/pdf
2. Hanafy, A. F., Abdalla, A. M., Guda, T. K., Gabr, K. E., Royall, P. G., &Alqurshi, A. (2019). Ocular anti-inflammatory activity of prednisolone acetate loaded chitosan-deoxycholate self-assembled nanoparticles. International journal of nanomedicine, 3679-3689. https://www.tandfonline.com/doi/pdf/10.2147/IJN.S195892?needAccess=true&role=button
3. Iftikhar, S. Y., Iqbal, F. M., Hassan, W., Nasir, B., & Sarwar, A. R. (2020). Desirability combined response surface methodology approach for optimization of prednisolone acetate loaded chitosan nanoparticles and in-

vitro assessment. Materials Research Express, 7(11), 115004. https://iopscience.iop.org/article/10.1088/2053-1591/abc772/pdf

4. Khater, A. J., Almurisi, S. H., Mahmood, S., Alheibshy, F., Alobaida, A., Abdul-Halim, N., & Chatterjee, B. (2022). A Review on Taste Masked Multiparticulate Dosage Forms for “paediatric”. International Journal of Pharmaceutics, 122571. https://www.sciencedirect.com/science/article/pii/S0378517322011267
5. Nieto González, N., Obinu, A., Rassu, G., Giunchedi, P., &Gavini, E. (2021). Polymeric and lipid nanoparticles: which applications in pediatrics?. Pharmaceutics, 13(5), 670. https://www.mdpi.com/1999-4923/13/5/670/pdf
6. Salunke, S., Brien, F. O., Tan, D. C. T., Harris, D., Math, M. C., Ariën, T., & Timpe, C. (2022). Oral drug delivery strategies for development of poorly water soluble drugs in “paediatric” patient population. Advanced Drug Delivery Reviews, 114507. https://discovery.ucl.ac.uk/id/eprint/10156905/1/1-s2.0-S0169409X22003970-main.pdf
7. Tawfik, E. A., Scarpa, M., Abdelhakim, H. E., Bukhary, H. A., Craig, D. Q., Barker, S. A., & Orlu, M. (2021). A potential alternative orodispersible formulation to prednisolone sodium phosphate orally disintegrating tablets. *Pharmaceutics*, *13*(1), 120. https://www.mdpi.com/965572